Based on the clinical findings.

This October Earlier, Agile announced the completion of individual enrollment ahead of schedule in its pivotal, Phase 3 NEW CHOICE Study of AG200-15. Dr. Marie Foegh, Chief Medical Vice and Officer President, Clinical Research and Advancement of Agile Therapeutics, stated, The reported Phase 2 outcomes demonstrate AG200-15 delivers a dose of estrogen sufficiently low in order to avoid increased threat of adverse events, but still effective in preventing undesirable episodes of breakthrough bleeding.This method will be made designed for use by scientists around the world for his or her own analysis in metabolomics studies. An interview with Professor Lesley JonesNew research from TSRI and Salk factors to reason behind debilitating nerve diseaseThe QTRAP 5500 System is normally a mass spectrometry program that integrates triple quadrupole and linear accelerator trap systems onto an individual platform for quicker and more accurate analysis of complex samples, making this operational system ideal for metabolomics, in addition to other areas of systems biology including lipidomics and proteomics. The QTRAP 5500 Program is a robust system on which to develop brand-new methods for quantifying metabolites that could after that be transferred into standard procedures in research laboratories around the world.